Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Trial details
- Registry ID
- NCT05844423
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsNCT05844423 | PCVX | Phase 2 | Completed | 2025-08-25Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |